Bhat Biotech sees need to prioritise adoption of rapid card for series of blood tests in accurate and speedy diagnosis

Bengaluru, July 30, 2022:

Bhat Biotech sees that accurate and simple diagnostics will transform the Indian healthcare landscape. This is even as diagnostic labs and accident-trauma emergency wings scout for advanced, simple to use, reliable yet cost effective rapid cards for blood tests.

This led the Bengaluru-based Bhat Biotech India to research, design and develop two products. One is the Bhat Bio Scan-- a Blood Grouping Rapid Test Card and the other is the HIV-Syphilis combi card test sold under the brand name Pareekshak.

Stating that the conventional blood grouping tests in labs is time consuming and needs to be stored at 4 degree centigrade before the analysis, Dr Shama Bhat, chairman and managing director, Bhat Biotech India said the Bhat Bio Scan Blood Grouping Rapid Test is based on immunochromatographic technology and provides an in-vitro recognition of the blood group antigens: A, B and D (Rh) on human red blood cells. It is highly specific and sensitive. The product is classified under category ‘D’ of medical devices and received the clearance from the Central Drugs Standards Control Organisation (CDSCO).

The demand for speed and reliability is much desired in today’s diagnostics. We see our Bhat Bio Scan Blood Grouping Rapid Test to be indispensable not just across blood donation drives and national health camps, but educational institutions, companies and government offices among others. The need for blood group identity is almost compulsory and soon could be mandatory not just for job seekers but also for school admission. Therefore such a rapid test card fits the bill, Dr Bhat told Pharmabiz in an interaction.

In the case of Pareekshak HIV-Syphilis combo card test, this will play a pivotal role in mother and child care in the country. It will stall the transmission of the disease from mother to child. It will be also used prior to gynec surgical interventions and for the drug abuse population.

Both our rapid card tests are set to make its presence felt in diagnostic labs and hospitals. They are positioned as safe, accurate, and fast detection devices. There are promising growth prospects. Global and national health organisations including WHO too have issued a directive on the need for single rapid tests. Even the National Rural Health Mission (NRHM) instructs for prevention, control and management of HIV-Syphilis to reduce reproductive morbidity among sexually active population, said Pavan Kumar M executive director and CEO, Bhat Biotech India.

Under the Union government Make in India, there is considerable importance given to local research and manufacture of rapid devices and we stand to garner a good market opportunity, said Kumar

While the company has laid a solid foundation in antigen test, going forward we are set to be engaged in molecular diagnostics for oncology and infectious diseases, said Dr Bhat. PharmaBiz